Market: NASD |
Currency: USD
Address: 500 West 5th Street
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.
📈 Shattuck Labs, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$2.00
-
Upside/Downside from Analyst Target:
101.41%
-
Broker Call:
6
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
25-50%
-
Net Income Growth Range (1Y):
25-50%
-
Revenue Growth Range (1Y):
<0%
-
Upcoming Earnings Date:
2025-11-13
-
EPS Estimate:
-0.15
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Shattuck Labs, Inc.
| Date | Reported EPS |
|---|
| 2025-11-13 (estimated upcoming) | - |
| 2025-08-14 | -0.24 |
| 2025-05-01 | -0.27 |
| 2025-03-27 | -0.37 |
| 2024-11-14 | -0.33 |
| 2024-08-01 | -0.42 |
| 2024-05-02 | -0.37 |
| 2024-02-29 | -0.41 |
| 2023-11-09 | -0.65 |
| 2023-08-10 | -0.5 |
| 2023-05-09 | -0.49 |
| 2023-02-23 | -0.6 |
| 2022-11-08 | -0.58 |
| 2022-08-11 | -0.65 |
| 2022-05-12 | -0.58 |
| 2022-03-15 | 0.19 |
| 2021-11-09 | -0.41 |
| 2021-08-11 | -0.56 |
| 2021-05-10 | -0.28 |
| 2021-03-15 | -0.31 |
| 2020-11-13 | -1.54 |
📰 Related News & Research
No related articles found for "shattuck labs".
